Objectives: To provide a single-institution analysis of the influence of pelvic intensity-modulated radiotherapy (RT) on acute genitourinary (GU) and gastrointestinal (GI) toxicity.
Methods: The records of 610 consecutive patients with prostate cancer receiving RT were reviewed. Of these 610 patients, 49 had received a prostate boost preceded by pelvic RT (PRT), 15 intensity-modulated PRT (IM-PRT), and 34 four-field PRT (4F-PRT). The dosimetric endpoints for the bladder, rectum, and target for the PRT plans were compared using the paired t test; similar dosimetric analyses were done for the composite plans. Acute GU and GI toxicity were compared using the chi-square test. Ordered logit regression analyses were performed using all major treatment factors as covariates.
Results: The bladder and rectum dosimetric endpoints were improved for IM-PRT compared with 4F-PRT for the PRT portion of the treatment plan (P = 0.06 and P = 0.03, respectively) and for the composite treatment plan (P = 0.04 and P = 0.01, respectively), at the expense of greater target inhomogeneity in the PRT portion of the treatment plan (P < 0.01). GU toxicity was significantly lower in the IM-PRT group (P < 0.001), and GI toxicity was similar in both groups (P = 0.637). The regression analyses showed that intensity-modulated RT for the pelvic portion of treatment was the only factor significantly predicting for GU toxicity (P = 0.05); no major treatment factor reached significance in predicting GI toxicity.
Conclusions: Compared with 4F-PRT, the use of IM-PRT improved dosimetric outcomes, was not associated with a reduction in acute GI toxicity, and was associated with a reduction in acute GU toxicity in the treatment of prostate cancer.